Payment overview · 2025
General Payments
$516.41
22 reported records · 10 companies
Healthcare provider profile · identity verified
Viktoriya Stepanyan
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · BURBANK, CA · NPI 1063159523
Verified facts
What the public records show
CMS Open Payments records show Viktoriya Stepanyan received $516.41 in general payments during 2025 across 22 reported records.
SHIELD THERAPEUTICS INC accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $199.52 | 38.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.00 | 10.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.52 | 10.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $48.76 | 9.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.88 | 7.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.73 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.55 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.86 | 4.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.20 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.39 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.44 | 21 |
| Education | $21.97 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $199.52 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.00 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.00 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 463 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 94 |
| Metformin Hcl | Metformin Hcl | 244 | 48 |
| Omeprazole | Omeprazole | 235 | 57 |
| Losartan Potassium | Losartan Potassium | 189 | 39 |
| Alendronate Sodium | Alendronate Sodium | 161 | 31 |
| Gabapentin | Gabapentin | 158 | 31 |
| Trazodone Hcl | Trazodone Hcl | 154 | 28 |
| Lisinopril | Lisinopril | 153 | 29 |
| Ibuprofen | Ibuprofen | 142 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 31 |
| Meclizine Hcl | Meclizine Hcl | 130 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 25 |
| Meloxicam | Meloxicam | 127 | 27 |
| Vascepa | Icosapent Ethyl | 104 | 29 |
| Simvastatin | Simvastatin | 98 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 81 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 11 |
| Linzess | Linaclotide | 58 | suppressed |
| Famotidine | Famotidine | 57 | 12 |
| Atenolol | Atenolol | 53 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 19 |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 13 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 14 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 12 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $516.41 · 22 records | SHIELD THERAPEUTICS INC | ACCRUFER, DUPIXENT, EVKEEZA, IBSRELA, JARDIANCE, MOUNJARO, NURTEC ODT, QULIPTA, Repatha, UBRELVY, VRAYLAR, XIFAXAN, ZAVZPRET, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error